2-噻吩羰基氯化,5-(甲硫基)-(9CI) | 135080-21-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 2-噻吩羰基氯化,5-(甲硫基)-(9CI)
• 中文别名: 5-(甲硫基)-2-噻吩甲酰氯
• 英文名称: 5-(methylthio)thiophene-2-carbonyl chloride
• 英文别名: 5-methylsulfanylthiophene-2-carbonyl chloride
• CAS: 135080-21-6
• 化学式: C₆H₅ClOS₂
• 分子量: 192.69
• InChiKey: CURVZWVYJDZXOE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  70.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-噻吩羰基氯化,5-(甲硫基)-(9CI) 在 氨 作用下， 以 乙醚 为溶剂， 生成 5-methylthiothiophen-2-carboxamide
  参考文献：
  名称：

  Alberghina, Gaetano; Fisichella, Salvatore; Occhipinti, Salvatore, Journal of the Chemical Society. Perkin transactions II, 1982, p. 1223 - 1226

  摘要：

  DOI：

文献信息

• [EN] MODULATORS OF REV-ERB<br/>[FR] MODULATEURS DE REV-ERB
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015103527A1

  公开（公告）日：2015-07-09

  The subject matter herein concerns the identification and development of potent synthetic REV-ERB ligands, such as in vivo agonists and antagonists. These compounds allow for characterization of the effects of modulation of this receptor in vivo specifically on circadian behavior and metabolism, and have suitable characteristics for development of medicinal compounds useful for treatment of malconditions such as diabetes, obesity, atherosclerosis, dyslipidemia, a circadian rhythm disorder, coronary artery disease, bipolar disorder, depression, cancer, a sleep disorder, an anxiety disorder, an addiction disorder, a bone-related disorder such osteoporosis, a skeletal muscle disease, e.g., with compromised exercise capacity, or an autoimmune disorder such as psoriasis, multiple sclerosis, inflammatory bowel disease, and others.

  本文涉及识别和开发强效合成REV-ERB配体，例如体内激动剂和拮抗剂。这些化合物可用于特定在体内对昼夜节律行为和新陈代谢的调节效果进行表征，并具有适合开发用于治疗糖尿病、肥胖症、动脉粥样硬化、血脂异常、昼夜节律紊乱、冠状动脉疾病、躁郁症、抑郁症、癌症、睡眠障碍、焦虑障碍、成瘾障碍、骨相关疾病如骨质疏松症、骨骼肌肉疾病（例如，运动能力受损）、自身免疫性疾病如牛皮癣、多发性硬化、炎症性肠病等疾病的药用化合物的特性。
• ALBERGHINA, G.;FISICHELLA, S.;OCCHIPINTI, S.;CONSIGLIO, G.;SPINELLI, D.;N+, J. CHEM. SOC. PERKIN TRANS., 1982, N 10, 1223-1225
  作者：ALBERGHINA, G.、FISICHELLA, S.、OCCHIPINTI, S.、CONSIGLIO, G.、SPINELLI, D.、N+

  DOI：——

  日期：——
• THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：GRIFFIOEN Gerard

  公开号：US20090054410A1

  公开（公告）日：2009-02-26

  This invention provides specifically substituted 1,2,4-thiadiazole derivatives for use in the treatment of an α-synucleopathy such as Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease. This invention also provides various methods for producing such substituted 1,2,4-thiadiazole derivatives.
• US8541406B2
  申请人：——

  公开号：US8541406B2

  公开（公告）日：2013-09-24
• Alberghina, Gaetano; Fisichella, Salvatore; Occhipinti, Salvatore, Journal of the Chemical Society. Perkin transactions II, 1982, p. 1223 - 1226
  作者：Alberghina, Gaetano、Fisichella, Salvatore、Occhipinti, Salvatore、Consiglio, Giovanni、Spinelli, Domenico、Noto, Renato

  DOI：——

  日期：——